Long-Term Efficacy, Safety, and Tolerability of Indinavir-Based Therapy in Protease Inhibitor-Naive Adults with Advanced HIV Infection

Clinical Infectious Diseases

Volumn 37, Issue 8, 2003, Pages 1119-1124

  Hirsch, Martin S ^a   Steigbigel, Roy T ^b   Staszewski, Scholomo ^g   McMahon, Deborah ^c   Fischl, Margaret A ^e   Hirschel, Bernard ^h   Squires, Kathleen ^f   DiNubile, Mark J ^d   Harvey, Charlotte M ^d   Chen, Joshua ^d   Leavitt, Randi Y ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INDINAVIR; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; VIRUS RNA; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROLITHIASIS; OPEN STUDY; PRIORITY JOURNAL; PROTEINURIA; PYURIA; RANDOMIZED CONTROLLED TRIAL; RNA ANALYSIS; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; URINALYSIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIARRHEA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; MALE; MIDDLE AGED; RNA, VIRAL; ZIDOVUDINE;

EID: 0142156151     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/378063     Document Type: Article

References (18)

1. Panel on Clinical Practices for the Treatment of HIV Infection convened by the Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http:// www.aidsinfo.nih.gov. Accessed 14 July, 2003.
2. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352: 1725-30.
3. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
4. Hoggs RS, Health KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279:450-4.
5. Vittinghoff E, Scheer S, O'Malley P, et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179:717-20.
6. Li TS, Tubiana R, Katlama C, et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-6.
7. Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13:963-9.
8. Casado JL, Perez-Elias MJ, Antela A, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998; 12:F131-5.
9. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-31.
10. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-33.
11. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-9.
12. Gulick RM, Mellors JW, Havlir D, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000; 133:35-9.
13. Gulick RM, Meibohm A, Halvir D, et al. Six-year follow-up of HIV-1 infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS (in press).
14. Hirsch MS, Steigbigel R, Staszewski S, et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis 1999; 180:659-65.
15. Sun R, Ku J, Jayakar H, et al. Ultrasensitive reverse transcriptase-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1998; 36:2964-9.
16. Kleinman KP, Ibrahim JG, Laird NM. A Bayesian framework for intent-to-treat analysis with missing data. Biometrics 1998; 54:265-78.
17. Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics 1996; 52:1324-33.
18. Tsiatis A. Methodological issues in AIDS clinical trials: intent-to-treat analysis. J Acquir Immune Defic Syndr 1990;3:S120-3.